Loading market dashboard
Exelixis, Inc.
EXELHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr.
When Wall Street's growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles.
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 11:05 a.m. ET / 8:05 a.m. PT on Wednesday, June 3 in New York City. Goldman Sachs 47th Annual Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 9 in Miami. To access the.
CHEVY CHASE, Md.--(BUSINESS WIRE)-- #Biotech--Caring Men Global, a nonprofit dedicated to supporting male caregivers facing a loved one's cancer, has received a grant from Exelixis to launch “Strong Caregivers, Stronger Survivors,” a caregiver-centered cancer recurrence prevention program designed to prepare men to effectively support cancer survivors following treatment. Survivors are often most vulnerable after active treatment ends, when medical oversight decreases and responsibility for prevention, mo.
Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven almost entirely by CABOMETYX demand; operating margin expanded to 41.1% as costs fell. I maintain a Buy rating with a $57 target, reflecting 13% upside; DCF and peer multiples confirm the valuation gap persists.
Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company's senior vice president of strategy, said during a session hosted by RBC Capital Markets.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago. “The presentations at ASCO this year highlight the continued progress of our strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the d.
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of th.
Exelixis's main product should continue driving growth through the end of the decade. The company is close to earning approval for a medicine that will take up the mantle thereafter.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026: Exelixis is scheduled to present at 1:00 p.m. ET / 10:00 a.m. PT on Tuesday, May 12 in Las Vegas. 2026 RBC Capital Markets Global Healthcare Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, May 19 in New York City. 2026 Stifel Vir.
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis made significant progress in the first quarter of 2026 as we remain focused on our goal of building next-generation oncology franchises,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, E.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon regist.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Financial Group LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 25.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,956 shares of the biotechnology company's stock after acquiring an additional 17,615 shares during
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
All three drugmakers have proven fairly innovative in their respective niches. Clinical and commercial progress could send their share prices soaring.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis is positioned to evolve into a multi-franchise oncology company, anchored by CABOMETYX and the emerging zanzalintinib. CABOMETYX remains a durable cash generator, while zanzalintinib is expected to drive significant growth, with peak sales estimates of $5B by 2033. 2026 guidance projects $2.52B–$2.62B in revenue, excluding potential zanzalintinib contributions, as the company maintains robust R&D and share repurchases.
Exelixis is undervalued, trading at a discount to sector and historical multiples despite robust double-digit growth and operational excellence. EXEL maintains high margins, generates strong FCF, and funds growth without increasing debt while aggressively repurchasing shares. Cabometyx drives most revenue, but management is investing heavily in R&D to diversify the portfolio and sustain future growth.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SG Americas Securities LLC boosted its stake in Exelixis, Inc. (NASDAQ: EXEL) by 72.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,288 shares of the biotechnology company's stock after purchasing an additional 15,203 shares during the quarter.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Explore the exciting world of Exelixis (EXEL +2.24%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Shares of Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) have earned an average recommendation of "Hold" from the twenty-three ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have given a buy rating and one has assigned
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results.
Center For Asset Management LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ: EXEL) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,371 shares of the biotechnology company's stock, valued at approximately $511,000. A number of other hedge funds have also recently
Top insights from the latest market news from Tuesday, March 17, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Presents at The Citizens Life Sciences Conference 2026 Transcript
CreativeOne Wealth LLC lifted its position in Exelixis, Inc. (NASDAQ: EXEL) by 135.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,102 shares of the biotechnology company's stock after buying an additional 18,495 shares during the period. CreativeOne Wealth
Barclays PLC increased its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 11.0% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 732,686 shares of the biotechnology company's stock after buying an additional 72,377 shares during the quarter. Barclays PLC owned about 0.27% of Exelixis worth
Exelixis, Inc. (EXEL) Presents at Leerink Global Healthcare Conference 2026 Transcript
Dimensional Fund Advisors LP increased its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 11.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,180,912 shares of the biotechnology company's stock after acquiring an additional 419,596 shares during the
Victory Capital Management Inc. boosted its stake in shares of Exelixis, Inc. (NASDAQ: EXEL) by 55.0% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 527,135 shares of the biotechnology company's stock after buying an additional 187,034 shares during the period. Victory Capital Management Inc.
